• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    11/3/25 4:31:03 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    gdrx-20251031
    0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192025-10-312025-10-31
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________
    FORM 8-K
    ________________________________________
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): October 31, 2025
    ________________________________________
    GoodRx Holdings, Inc.
    (Exact Name of Registrant as Specified in its Charter)
    ________________________________________
    Delaware
    001-39549
    47-5104396
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    2701 Olympic Boulevard
    Santa Monica, California
    90404
    (Address of Principal Executive
    Offices)
    (Zip Code)
    Registrant’s Telephone Number, Including Area Code: (855) 268-2822
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
    registrant under any of the following provisions:
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Class A Common Stock, $0.0001 par value per
    share
    GDRX
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
    of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
    period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
    Exchange Act. ☐
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
    Compensatory Arrangements of Certain Officers.
    On October 31, 2025, GoodRx Holdings, Inc. (the “Company”) and Trevor Bezdek, the Company’s Co-Chairman of
    the Board of Directors (the “Board”), mutually agreed to end Mr. Bezdek’s employment and executive officer service with the
    Company and its subsidiaries upon the expiration of his employment agreement on November 1, 2025. Mr. Bezdek will
    continue to serve as a Co-Chairman of the Board as a non-employee director.
    Compensation of Mr. Bezdek
    Following his termination of employment, as a non-employee director, Mr. Bezdek will be eligible to receive the
    standard compensation received by non-employee directors under the Company’s second amended and restated Non-
    Employee Director Compensation Program (the “A&R Director Compensation Program”) and will be permitted to participate
    in the Deferred Compensation Plan for Directors (the “Deferred Compensation Plan”). Under the A&R Director
    Compensation Program, Mr. Bezdek will be eligible to receive (i) an annual cash retainer of $30,000 for his service on the
    Board (pro-rated based on his service as a non-employee director during the 2025 fiscal year), (ii) an additional annual cash
    retainer of $10,000 for his service as the member of the Nominating and Corporate Governance Committee (pro-rated
    based on his service during the 2025 fiscal year) (iii) an additional annual cash retainer of $75,000 for his service as Co-
    Chair of the Board (pro-rated based on his service during the 2025 fiscal year and to which Scott Wagner will also be
    entitled) and (iv) if serving on the Board as of the date of the annual meeting of the Company’s stockholders for a given
    calendar year, an annual award of restricted stock units (“RSUs”) with a value of $230,000 granted on such annual meeting
    date. Additionally, in connection with Mr. Bezdek’s transition to a non-employee director, the Board, based on the
    recommendation of its Compensation Committee, granted Mr. Bezdek (a) a one-time initial award of RSUs with a value of
    $420,000, which will vest as to one-third of the shares underlying the grant on each of the first three anniversaries of the
    grant date, subject to continued service through the applicable vesting date; and (b) an award of RSUs with a value of
    $134,219, which will vest in full on the earlier of (i) June 3, 2026 and (ii) the date of the 2026 Annual Meeting of
    Stockholders, subject to continued service through the applicable vesting date. These awards were granted effective on
    November 2, 2025, and the number of RSUs underlying each award was determined by dividing the applicable award value
    by the average closing price for the Company’s Class A common stock over the 30 calendar days preceding the grant dates.
    Pursuant to the Deferred Compensation Plan, Mr. Bezdek will be permitted to defer (i) all or a portion of his annual
    cash retainers (including any cash retainers for service on a committee) earned under the A&R Director Compensation
    Program and (ii) the settlement of any of his RSU awards granted under the A&R Director Compensation Program beyond
    the applicable vesting period in accordance with the terms and conditions set forth in the Deferred Compensation Plan.
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
    to be signed on its behalf by the undersigned hereunto duly authorized.
    GOODRX HOLDINGS, INC.
    Date:
    November  3, 2025
    By:
    /s/ Christopher McGinnis
    Name: Christopher McGinnis
    Title: Chief Financial Officer & Treasurer
    Get the next $GDRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Mizuho initiated coverage on GoodRx with a new price target

    Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

    12/4/24 7:38:07 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

    8/9/24 7:30:17 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:31:17 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:23:32 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/3/25 4:31:03 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    Director Bezdek Trevor was granted 33,530 shares, increasing direct ownership by 26% to 160,082 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/3/25 7:59:39 PM ET
    $GDRX
    EDP Services
    Technology

    Director Wagner Scott was granted 3,065 shares, increasing direct ownership by 2% to 185,269 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/3/25 7:57:02 PM ET
    $GDRX
    EDP Services
    Technology

    Director Hirsch Douglas Joseph converted options into 20,521 shares, increasing direct ownership by 10% to 231,909 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    10/27/25 5:54:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment

    The all-in-one solution includes a virtual consultation, clinically proven prescription medication, and discreet home delivery, starting as low as $16/month GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription for hair loss treatment. Built for simplicity and transparency, GoodRx for Hair Loss helps men access affordable treatments that are clinically proven to slow hair loss and support regrowth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014655126/en/GoodRx for Hair Loss Hair loss is one of the most common health concerns among men. By age 50,

    10/15/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology